Skip to main content

Table 1 Baseline characteristics of the study patients

From: Systolic and diastolic dysfunction affects kidney outcomes in hospitalized patients

Variable Total (n = 1327) Non-AKI (n = 1117) AKI (n = 210) P
Age (year) 66.2 ± 13.4 66.1 ± 0.4 66.9 ± 1.1 0.104
Men (%) 52.4 52.8 50.0 0.453
Body mass index (kg/m2) 24.2 ± 3.7 24.3 ± 0.1 23.2 ± 0.3 < 0.001
Systolic BP (mmHg) 129.5 ± 20.0 130.3 ± 0.6 125.5 ± 1.6 0.001
Diastolic BP (mmHg) 73.6 ± 12.7 74.3 ± 0.4 70.3 ± 1.0 < 0.001
Comorbidities (%)
 Hypertension 42.0 40.5 50.0 0.010
 Diabetes mellitus 32.4 28.6 52.4 < 0.001
 Ischemic heart disease 21.1 23.3 9.0 < 0.001
 Cerebrovascular disease 6.1 6.2 5.7 0.797
 Heart failure 2.1 1.5 5.2 0.001
 Cancer 31.3 29.8 39.5 0.005
Medications (%)
 Alpha blocker 0.9 0.6 2.4 0.014
 ACE inhibitor 5.3 4.8 7.6 0.098
 ARB 17.9 17.0 22.4 0.062
 Beta-blocker 18.6 19.2 15.7 0.239
 Calcium channel blocker 16.5 14.8 25.7 < 0.001
 Diuretics 14.0 9.2 4.8 < 0.001
Laboratory findings
 Hemoglobin (g/dL) 12.2 ± 2.1 12.4 ± 0.06 10.9 ± 0.1 < 0.001
 Albumin (g/dL) 3.9 ± 0.6 3.9 ± 0.02 3.5 ± 0.04 < 0.001
 Glucose (mg/dL) 134.3 ± 56.8 130.4 ± 1.6 149.6 ± 4.8 < 0.001
 Cholesterol (mg/dL) 157.3 ± 41.6 160.3 ± 1.2 141.6 ± 3.3 < 0.001
 eGFR (ml/min/1.73 m2) 82.5 ± 24.1 83.0 ± 20.6 79.9 ± 37.7 0.376
Echocardiographic findings
 LVMI (g/m2) 95.8 ± 26.5 95.3 ± 0.8 98.5 ± 2.1 0.220
 EF (%) 61.6 ± 8.8 61.9 ± 0.3 60.3 ± 0.7 0.027
 E/A 0.9 ± 0.4 0.9 ± 0.01 0.9 ± 0.03 0.228
 E/e’ 10.3 ± 4.9 10.1 ± 0.1 11.6 ± 0.4 0.001
 RWMA (%) 8.8 8.6 10.0 0.510
  1. AKI acute kidney injury, BP blood pressure, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, eGFR estimated glomerular filtration rate, LVMI left ventricular mass index, EF ejection fraction, E early diastolic transmitral inflow velocity, A late diastolic transmitral flow velocity, e’ early diastolic mitral annular velocity, RWMA regional wall motion abnormality